Hemodynamic Effect of Dexmedetomidine Versus Magnesium Sulphate as an Adjuvant to Lidocaine in Preemptive Peribulbar Block in Patients Undergoing Dacryocystorhinostomy Under General Anesthesia
Hemodynamic Effect of Dexmedetomidine Versus Magnesium Sulphate as an Adjuvant to Lidocaine in Preemptive Peribulbar Block in Patients Undergoing Dacryocystorhinostomy Under General Anesthesia: A Randomized Controlled Trial
Cairo University
60 participants
May 16, 2026
INTERVENTIONAL
Conditions
Summary
This study aims to compare the hemodynamic effect of dexmedetomidine and magnesium sulphate as an adjuvant to lidocaine in preemptive peribulbar block in patients undergoing Dacryocystorhinostomy (DCR) under general anaesthesia (GA) .
Eligibility
Inclusion Criteria4
- Age ≥ 18 years.
- Both sexes.
- American Society of Anesthesiologists (ASA) physical status I or II.
- Undergoing elective Dacryocystorhinostomy (DCR) surgery under general anesthesia.
Exclusion Criteria5
- Patients have local infection.
- Allergic reaction or complications of the local anaesthesia (LA).
- Coagulopathy defined as international normalized ratio (INR) > 1.5, platelet count < 100,000/mm³, or ongoing anticoagulant therapy not adequately discontinued.
- Uncontrolled systemic disease, defined as poorly controlled hypertension \[systolic blood pressure (SBP) > 160 mmHg\], uncontrolled diabetes mellitus (HbA1c > 8.5%), unstable ischemic heart disease, or decompensated hepatic or renal disease.
- Uncooperative patients.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will receive 5 ml of lidocaine 2% + 50 µg dexmedetomidine, with a total volume of 7 ml.
Patients will receive 5 ml of lidocaine 2% + 100 mg magnesium sulphate 10%, with a total volume of 7 ml.
Patients will receive 7 ml of lidocaine 2% with no further additives.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07675616